By: ICN Bureau
Last updated : May 14, 2025 9:00 pm
The Agrochemical sector has maintained its upward momentum this quarter, fueled by sales growth on both a year-over-year and quarter-over-quarter basis
Jubilant Ingrevia Ltd. has announced the financial results for Financial Year 2025 and Q4 FY2025 ended March 31, 2025.
During the quarter ended March 31, 2025, the company has posted Total Revenue of Rs. 1,051 crore as compared to Rs. 1,074 crore in Q4 FY24, reflecting a drop of 2 per cent. The company posted 153% jump in its PAT at Rs. 74 crore in Q4 FY25 as compared to Rs. 29 crore in Q4 FY24. The company's EBITDA margin also grew from 9% in Q4 FY24 to 15% in Q4 FY25.
For FY25, Jubilant Ingrevia has reported Total Revenue of Rs. 4,178 crore as compared to Rs. 4,136 crore in FY24. The company posted net profit of Rs. 251 crore as compared to Rs. 183 crore in FY24, reflecting a jump of 37 per cent.
“We are pleased to announce the sustained growth in revenue and margins for our Specialty Chemicals and Nutrition businesses. Our ongoing cost reduction efforts have further boosted our profitability, with quarter’s EBITDA margin reaching 14.7% and Profit After Tax increasing by 153% on YoY basis,” the company said in a statement.
The Board has recommended a final dividend of 250% i.e. Rs 2.50 per equity share of face value of Re 1 each for the FY’25. This shall result in cash outflow of Rs. 39.8 crore. During the year, the company has declared an interim dividend of 250% i.e. Rs 2.50 per equity share of Rs 1 each and the total dividend for FY’25 works out to be 500% i.e. Rs 5 Per equity share of Rs 1 each amounting to Rs. 79.8 crore of Cash outflow.
Markets Update:
“The global chemicals and specialty chemicals sector has largely moved past the inventory destocking phase, showing volume recovery in specialty materials. The commodity segments continue to have volume under pressure though. Prices remain muted across segments, and have stabilized at a new normal.
The Pharmaceutical End-Use market is experiencing steady demand, supported by stable pricing and consistent volume placements. Our Pharma portfolio within the Fine Chemicals business reflects these positive trends.
However, we continue to face low volumes in the Acetyls business due to low demand in the Paracetamol segment. The Agrochemical sector has maintained its upward momentum this quarter, fueled by sales growth on both a year-over-year and quarter-over-quarter basis. Consequently, average prices in the sector have shown signs of recovery, suggesting potential price improvements during the ensuing quarters.
The Nutrition market saw a consistent rise in volumes. Niacinamide demand held steady, with prices remaining stable throughout the quarter. Meanwhile, Choline demand experienced a notable surge, though its pricing remained under pressure due to China imports.
In light of the recent global tariffs imposed by the US Government, we are pleased to report that the impact on our US sales has been minimal. Approximately 10% of our total sales are in the US, and only 25% of those fall under dutiable items. This means that just 2.5% of our overall global sales might be affected by the US tariffs.
Additionally, with potentially higher tariffs on Chinese exports to the US compared to Indian exports, we anticipate favourable conditions for both volume and pricing in our US export portfolio in the coming quarters.
Business Update:
In the Specialty Chemicals Business segment, overall volumes remained stable. We are observing continuous growth momentum across our Pyridine & Picoline, Fine Chemicals and CDMO businesses, with an expanded pipeline of newer opportunities for coming quarters. In certain segments, we have started to see slight price uptick as well.
The Nutrition and Health Solutions Business segment saw substantial YoY and QoQ volume growth, primarily fueled by significant increases in choline product volumes, while Niacinamide volumes remained stable. Pricing within the segment remained stable throughout the quarter.
We are witnessing strong interest and customer enquiries in our human and cosmetic grade products and anticipate increasing production at our newly commissioned cGMP-compliant Niacinamide plant at Bharuch, Gujarat in the coming quarters.
In the Chemical Intermediates Business segment, we observed sustained growth in Ethyl Acetate sales volumes both QoQ and YoY. However, Acetic Anhydride volumes remained low due to weak demand from the Paracetamol sector. Overall, prices in this segment stayed relatively benign, which affected our margins.”